SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 23, Issue 8, 2005, Pages 1596-1597

Prognostic and predictive factors for breast cancer: Translating technology to oncology

(1) Hayes, Daniel F a

a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; DISEASE MARKER; EDITORIAL; FOLLOW UP; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; METASTASIS; ONCOLOGY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; BIOTECHNOLOGY; BREAST TUMOR; FEMALE; NOTE; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

BIOTECHNOLOGY; BREAST NEOPLASMS; FEMALE; HUMANS; MEDICAL ONCOLOGY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 15544372843 PISSN: 0732183X EISSN: None Source Type: Journal
DOI: 10.1200/JCO.2005.10.074 Document Type: Editorial

Times cited : (33)

References (8)

1
- 0032537396
- Tamoxifen for early breast cancer: An overview of the randomised trials
- Early Breast Cancer Trialist's Collaborative Group
- Early Breast Cancer Trialist's Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
- (1998) Lancet , vol.351 , pp. 1451-1467

2
- 0032547564
- Polychemotherapy for early breast cancer: An overview of the randomized trials
- Early Breast Cancer Trialist's Collaborative Group
- Early Breast Cancer Trialist's Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352: 930-942, 1998
- (1998) Lancet , vol.352 , pp. 930-942

3
- 0035869407
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
- Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
- (2001) N Engl J Med , vol.344 , pp. 783-792
- Slamon, D.J.¹ Leyland-Jones, B.² Shak, S.³

4
- 0036467826
- Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
- Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
- (2002) J Clin Oncol , vol.20 , pp. 719-726
- Vogel, C.L.¹ Cobleigh, M.A.² Tripathy, D.³

5
- 15544384884
- Gene expression profiling of breast cancer: A new tumor marker
- van't Veer LJ, Paik S, Hayes DF: Gene expression profiling of breast cancer: A new tumor marker. J Clin Oncol 23:1631-1635, 2005
- (2005) J Clin Oncol , vol.23 , pp. 1631-1635
- van't Veer, L.J.¹ Paik, S.² Hayes, D.F.³

6
- 15544388390
- Circulating and disseminated tumor cells
- Braun S, Name B: Circulating and disseminated tumor cells. J Clin Oncol 23:1623-1626, 2005
- (2005) J Clin Oncol , vol.23 , pp. 1623-1626
- Braun, S.¹ Name, B.²

7
- 15544387129
- Physician/patient decision aids for adjuvant therapy
- Whelan TJ, Loprinzi C: Physician/patient decision aids for adjuvant therapy. J Clin Oncol 23:1627-1630, 2005
- (2005) J Clin Oncol , vol.23 , pp. 1627-1630
- Whelan, T.J.¹ Loprinzi, C.²

8
- 0034690750
- UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years
- Peto R, Boreham J, Clarke M, et al: UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355:1822, 2000
- (2000) Lancet , vol.355 , pp. 1822
- Peto, R.¹ Boreham, J.² Clarke, M.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.